Erin Luea

Senior Scientist

Erin Luea is the Senior Scientist in the Toxicology Department. She brings more than 13 years of drug development experience in the execution, design, conduction, project management and reporting of regulated toxicology studies in support of IND applications for pharmaceutical and biotechnology companies.

Luea’s experience includes in vivo toxicology studies, safety pharmacology, safety pharmacology, and pharmacokinetic assessments in multiple species. She has detailed knowledge of FDA and OECD guidances that pertain to the design and conduct of general and specialized toxicology studies. Her areas of expertise include the safety assessment of oncolytic therapeutics and viral vectors. Luea also has more than 11 years of project team experience and has managed many outsourced bioanalytical, pharmacokinetic, and GLP toxicology studies. She has been on the project teams for more than 20 IND submissions for regulatory approval and has successfully fielded investigator questions during the approval process.

Related Articles

Southern Research opens new Station 41 biotech incubator for startups

January 23, 2024

Today, Southern Research marked the official opening of its Station 41 biotech incubator, which is one of four programs that make up the newly launched Station 41 biotech commercialization hub. The incubator provides wet lab space and office space, shared lab equipment and services to support bio...
Read More

Birmingham receives federal Tech Hub designation and opportunity to apply for millions in federal funding

October 23, 2023

Birmingham’s metro area is among 31 regions across the country named today as a federal Tech Hub, competing successfully under a new program that could ultimately inject $75 million into the local economy. The designation followed a highly competitive process with nearly 200 applications natio...
Read More

Southern Research launches Venture Studio

November 22, 2022

Southern Research has launched a Venture Studio to develop startups that will bring new therapeutic products to market. In conjunction with its partners, Southern Research has more than 20 drug programs currently in preclinical development. These programs hold enormous potential for patients in t...
Read More